Michael Vanden Oever

Michael OeverDepartment

Pediatric Hematology, Oncology and BMT


Microbiology, Immunology and Cancer Biology (MICAB) Ph.D. Program


Jakub Tolar, MD, PhD

Project description

Recessive Dystrophic Epidermolysis Bullosa (RDEB) is a severe inherited skin disorder characterized by loss of skin integrity and chronic blistering. Complications such as systemic infections and aggressive squamous cell carcinoma are common and life-threatening for individuals with this disorder. Recently, cell based therapies including blood and marrow transplantation (BMT) have shown to be effective in ameliorating this disease, but certain aspects of this treatment are not well characterized. RDEB is caused by mutations in COL7A1, the gene encoding for type VII collagen, which is the principal component of anchoring fibrils that form at the dermal-epidermal junction. My research aims to better understanding how the various compounds in the BMT preparative regimen affect type VII collagen expression in hopes to improve upon the use of BMT in treating RDEB, as well as working on developing other novel therapies in treating this disease.


Caspase 9 Is Essential for Herpes Simplex Virus Type 2-Induced Apoptosis in T Cells. Michael J. Vanden Oever, Jin-Young Han. J Virol. 2010 March; 84(6): 3116–3120